Study to Evaluate Efficacy and Safety of S303 Treated Red Blood Cells (RBCs)in Subjects With Thalassemia Major Requiring Chronic RBC Transfusion
A Randomized Controlled Study to Evaluate Efficacy and Safety of S 303 Treated Red Blood Cells (RBC) in Subjects With Thalassemia Major Requiring Chronic RBC Transfusion
Sponsor: Cerus Corporation
This PHASE3 trial investigates Thalassemia Major and is currently completed. Cerus Corporation leads this study, which shows 8 recorded versions since 2012 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
8 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE3
-
Aug 2018 — Jan 2021 [monthly]
Completed PHASE3
Status: Active Not Recruiting → Completed
▶ Show 3 earlier versions
-
Jun 2018 — Aug 2018 [monthly]
Active Not Recruiting PHASE3
-
Jan 2018 — Jun 2018 [monthly]
Active Not Recruiting PHASE3
-
Jan 2017 — Jan 2018 [monthly]
Active Not Recruiting PHASE3
First recorded
Dec 2012
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Cerus Corporation
For direct contact, visit the study record on ClinicalTrials.gov .